PolyActiva and RareSight announced a strategic collaboration to develop first-in-class therapies for rare pediatric retinal diseases currently lacking approved drug treatments. The collaboration leverages PolyActiva’s PREZIA platform to create sustained-release, intravitreally administered treatments that deliver medication directly to the retina without requiring patient administration—a benefit for children and caregivers.

PolyActiva's PREZIA platform delivers zero-order, long-acting pharmacologic therapies as first-of-its-kind pro-drug candidates. The company’s clinical-stage portfolio includes PA5108, a biodegradable ocular microimplant designed for sustained IOP control for up to 6 months. PolyActiva is currently conducting a Phase 2b trial in the United States in approximately 75 patients across 12 sites to evaluate PA5108’s safety, tolerability, and durability.

“This collaboration represents an important step in PolyActiva’s growth as we expand our proprietary platform into new therapeutic areas,” said Jerry St. Peter, CEO of PolyActiva. “Partnering with RareSight allows us to apply our PREZIA technology beyond glaucoma to address the urgent unmet needs of children living with inherited retinal disorders.”

Carmen Caricchio, CEO and Founder of RareSight, added, “By combining RareSight’s therapeutic discovery and development expertise with PolyActiva’s novel drug delivery platform, this collaboration represents a major step toward transforming how inherited eye diseases are treated.”